ALVO vs. QGEN, ELAN, BBIO, MRNA, VRNA, RVMD, GRFS, RYTM, RNA, and ABVX
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Qiagen (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.
Alvotech vs. Its Competitors
Alvotech (NASDAQ:ALVO) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.
Qiagen has a net margin of 18.30% compared to Alvotech's net margin of 11.26%. Qiagen's return on equity of 14.77% beat Alvotech's return on equity.
In the previous week, Alvotech had 2 more articles in the media than Qiagen. MarketBeat recorded 7 mentions for Alvotech and 5 mentions for Qiagen. Qiagen's average media sentiment score of 0.72 beat Alvotech's score of 0.55 indicating that Qiagen is being referred to more favorably in the news media.
Alvotech presently has a consensus price target of $14.00, indicating a potential upside of 63.93%. Qiagen has a consensus price target of $49.40, indicating a potential upside of 5.34%. Given Alvotech's higher possible upside, equities analysts clearly believe Alvotech is more favorable than Qiagen.
Qiagen has higher revenue and earnings than Alvotech. Qiagen is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
Alvotech has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
70.0% of Qiagen shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Qiagen beats Alvotech on 11 of the 15 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alvotech Competitors List
Related Companies and Tools
This page (NASDAQ:ALVO) was last updated on 10/6/2025 by MarketBeat.com Staff
